Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Income (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of Net Income data on record, last reported at -$19.5 million in Q4 2024.

  • For Q4 2024, Net Income rose 19.09% year-over-year to -$19.5 million; the TTM value through Sep 2025 reached -$19.5 million, up 78.62%, while the annual FY2024 figure was -$86.6 million, 11.99% up from the prior year.
  • Net Income reached -$19.5 million in Q4 2024 per FHTX's latest filing, down from -$19.1 million in the prior quarter.
  • Across five years, Net Income topped out at -$14.0 million in Q1 2020 and bottomed at -$30.5 million in Q1 2023.
  • Average Net Income over 5 years is -$23.3 million, with a median of -$23.9 million recorded in 2021.
  • Peak YoY movement for Net Income: tumbled 68.9% in 2021, then surged 44.33% in 2023.
  • A 5-year view of Net Income shows it stood at -$21.1 million in 2020, then crashed by 35.11% to -$28.5 million in 2021, then fell by 1.33% to -$28.9 million in 2022, then grew by 16.55% to -$24.1 million in 2023, then rose by 19.09% to -$19.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Net Income were -$19.5 million in Q4 2024, -$19.1 million in Q3 2024, and -$23.0 million in Q2 2024.